Pulmonary complications (as defined by study authors, including pneumonia, embolism, reduced pulmonary function, prolonged ventilation, and pleural effusion, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids may leads to lower pulmonary complications (as defined by study authors, including… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review
Infectious complications · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids may leads to lower infectious complications (as defined by study authors, including… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review
Gastrointestinal bleeding · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids showed no clear difference in gastrointestinal (GI) bleeding (as defined by study authors,… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review
Renal failure · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids showed no clear difference in renal failure (as defined by study authors, including dialysis,… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review
Length of stay · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
1 finding from 1 review
Disease‐specific mortality ‐ SJS and TEN (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
It is very uncertain whether corticosteroids changes disease‐specific mortality ‐ SJS and TEN (time to compared with no corticosteroids (very low certainty).
1 finding from 1 review
Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in hearing threshold determined by PTA Range 0 dB to 140 dB Negative values represent lowering and positive values represent raising of the hearing threshold. A lower hearing threshold represents hearing improvement. Â · sudden sensorineural hearing loss
Intratympanic corticosteroids showed no clear difference in change in hearing threshold determined by PTA Range 0 dB to 140 dB… compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Proportion of patients whose hearing is improved · sudden sensorineural hearing loss
Intratympanic corticosteroids showed no clear difference in proportion of patients whose hearing is improved compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
Final hearing threshold determined by PTA (a lower value represents better hearing) · sudden sensorineural hearing loss
Intratympanic corticosteroids showed no clear difference in final hearing threshold determined by PTA (a lower value represents… compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Adverse eventsb · sudden sensorineural hearing loss
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tympanic membrane perforation · sudden sensorineural hearing loss
1 finding from 1 review
Vertigo/dizziness: timing not reported · sudden sensorineural hearing loss
Intratympanic corticosteroids may leads to higher vertigo/dizziness: timing not reportedd compared with systemic corticosteroids (low certainty).
1 finding from 1 review
Vertigo/dizziness: at the time of injection · sudden sensorineural hearing loss
1 finding from 1 review
Ear pain: timing not reported · sudden sensorineural hearing loss
Intratympanic corticosteroids probably leads to higher ear pain: timing not reportedf compared with systemic corticosteroids (moderate certainty).
1 finding from 1 review
Ear pain: at the time of injection · sudden sensorineural hearing loss
1 finding from 1 review
Relapse · patients with acute asthma
Intramuscular corticosteroids showed no clear difference in relapse compared with oral corticosteroids (low certainty).
3 findings from 1 review
RR 0.94 [0.72, 1.24]
9 studies · 804 participants
Low
RR 0.74 [0.51, 1.07]
7 studies · 742 participants
Moderate
RR 0.99 [0.74, 1.33]
5 studies · 556 participants
Low